Search Results
372 results found-
Should you get both vaccinations? Yes, says an infectious disease doctor with the U.S. National Foundation for Infectious Diseases.
https://www.csl.com/we-are-csl/vita-original-stories/2021/protecting-yourself-from-covid-19-and-influenza -
CSL presents the World of Promise podcast series, focused on the promise of biotechnology.
https://www.csl.com/we-are-csl/csl-podcasts -
CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth. Learn more.
https://www.csl.com/research-and-development/product-pipeline -
In 2022, flu cases in Australia have spiked earlier and with more cases this season than the previous five for the same time period. Experts discuss global implications of the surge.
https://www.csl.com/we-are-csl/vita-original-stories/2022/flu-is-making-a-resurgence -
CSL Seqirus delivered a record 135 million doses of flu vaccines globally last year, here’s how we make such a feat happen.
https://www.csl.com/we-are-csl/vita-original-stories/2022/the-art-and-science-of-shipping-flu-vaccines -
Jackson Free Clinic had trouble accessing flu vaccines, here's the story of how we made a difference.
https://www.csl.com/we-are-csl/vita-original-stories/2022/keeping-our-promise-to-patients-in-jackson-mississippi -
Even prior to the Omicron variant, U.S. experts urged four COVID-19 shots for this group after research found the vaccines produced a weaker immune response in those with primary immunodeficiency.
https://www.csl.com/we-are-csl/vita-original-stories/2021/three-shots-and-a-booster-for-immune-compromised-patients -
Get tips for overcoming “trypanophobia” so health care visits go smoothly.
https://www.csl.com/we-are-csl/vita-original-stories/2021/fear-of-needles-is-a-sticking-point -
The accomplished scientist offers this advice: “Like those early days, we need to play hard to our competitive advantages.”
https://www.csl.com/we-are-csl/vita-original-stories/2021/andrew-cuthbertson-reflects-on-25-years-with-csl -
Early research shows the potential of sa-mRNA “as the next generation of influenza vaccine technology,” says Roberta Duncan, who is leading the mRNA program at global flu vaccine leader Seqirus.
https://www.csl.com/we-are-csl/vita-original-stories/2022/stat-news-highlights-sa-mrna